Comparative frequencies of HIV low-level viremia between real-time viral load assays at clinically relevant thresholds

Journal of Clinical Virology

Volumn 52, Issue SUPPL. 1, 2011, Pages

  Do, Tri ^a,b   Duncan, John ^a   Butcher, Ann ^a   Liegler, Teri ^b  

^a Roche Molecular Diagnostics Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

End point PCR; HIV antiretroviral management; HIV low level viremia; HIV viral load; Real time PCR

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOASSAY; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UNITED STATES; VIRUS LOAD; VIRUS STRAIN;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; UNITED STATES; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 83155180374     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.09.022     Document Type: Article

References (31)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. January 10, 2011; 1-166 [accessed 13.3.11]. http://www.aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf.
2. Havlir D.V., Bassett R., Levitan D., Gilbert P., Tebas P., Collier A.C., et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001, 286:171-179.
3. Scott L., Carmona S., Stevens W. Performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay. J Clin Microbiol 2009, 47:3400-3402.
4. Damond F., Avettarnd-Fenoel V., Collin G., Roquebert B., Plantier J.C., Ganon A., et al. Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification. J Clin Microbiol 2010, 48:1413-1416.
5. Sizmann D., Glaubitz J., Simon C.O., Goedel S., Buergisser P., Drogan D., et al. Improved HIV-1 RNA quantitation by COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 using a novel dual-target approach. J Clin Virol 2010, 49:41-46.
6. Tang N., Huang S., Salituro J., Mak W.B., Cloherty G., Johanson J., et al. A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J Virol Methods 2007, 146(December (1-2)):236-245.
7. Ruelle J., Jnaoui K., Lefèvre I., Lamarti N., Goubau P. Comparative evaluation of the VERSANT HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral load. J Clin Virol 2009, 44(April (4)):297-301.
8. Scott L.E., Noble L.D., Moloi J., Erasmus L., Venter W.D., Stevens W. Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays. J Clin Microbiol 2009, 47(July (7)):2209-2217.
9. Paba P., Fabeni L., Ciccozzi M., Perno C.F., Ciotti M. Performance evaluation of the COBAS/TaqMan HIV-1 v2.0 in HIV-1 positive patients with low viral load: a comparative study. J Virol Methods 2011, 173(May (2)):399-402.
10. Bourlet T., Signori-Schmuck A., Roche L., Icard V., Saoudin H., Trabaud M.A., et al. HIV-1 load comparison using four commercial real-time assays. J Clin Microbiol 2011, 49(January (1)):292-297.
11. Ssebugenyi I., Kizza A., Mpoza B., Aluma G., Boaz I., Newell K., Laeyendecker O., Shott J.P., Serwadda D., Reynolds S.J. Comparison of the Abbott m2000 HIV-1 Real-Time and Roche AMPLICOR Monitor v1.5 HIV-1 assays on plasma specimens from Rakai, Uganda. Int J STD AIDS 2011, 22(July (7)):373-375.
12. Lima V., Harrigan R., Montaner J.S. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 2009, 51:3-6.
13. Montaner J.S.G., Richman D.D., Hammer S.M. on behalf of the International AIDS Society-USA Antiretroviral Guidelines Panel. Poor agreement between 2 assays for measuring low levels of HIV-1 viral load. Clin Infect Dis 2009, 49:1283-1284.
14. Smit E., Bhattacharya S., Osman H., Taylor S. Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay. J Acquir Immune Defic Syndr 2009, 51:362-365.
15. Szabo S., Moffett L.E., Cantwell-McNelis K., James C.W., Joseph A. Low-level viremia associated with the use of TaqMan assay. J Int Assoc Physicians AIDS Care (Chic) 2010, 9:203-205.
16. de Boer M.G.J., Wessels E., Claas E.C.J., Kroon F.P. Potential influence of more-sensitive HIV-1 load detection by the new Roche Cobas AmpliPrep/Cobas TaqMan version 2.0 assay on clinical management of HIV-positive pregnant women. J Clin Microbiol 2010, 48:4301-4302.
17. Verhofstede C., Van Wanzeele F., Reynaerts J., Mangelschots M., Plum J., Fransen K. Viral load assay sensitivity and low level viremia in HAART treated HIV patients. J Clin Virol 2010, 47:335-339.
18. Gatanaga H., Tsukada K., Honda H., Tanuma J., Yazaki H., Watanabe T., et al. Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clin Infect Dis 2009, 48:260-262.
19. Pascual-Pareja J.F., Martínez-Prats L., Luczkowiak J., Fiorante S., Rubio R., Pulido F., et al. Detection of HIV-1 at between 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1 v2.0 assay is associated with higher pretherapy viral load and less time on antiretroviral therapy. J Clin Microbiol 2010, 48:1911-1912.
20. Manavi K. The significance of low-level plasma HIV viral load on COBAS TaqMan HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor monitor version 1.5. HIV Clin Trials 2008, 9:283-286.
21. Berry N., Jaffar S., Schim van der Loeff M., Ariyoshi K., Harding E., N'Gom P.T., et al. Low level viremia and high CD4% predict normal survival in a cohort of HIV type-2-infected villagers. AIDS Res Hum Retroviruses 2002, 18:1167-1173.
22. Sklar P.A., Ward D.J., Baker R.K., Wood K.C., Gafoor Z., Alzola C.R., et al. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 2002, 16:2035-2041.
23. Karlsson A.C., Younger S.R., Martin J.N., Grossman Z., Sinclair E., Hunt P.W., et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 2004, 18:981-989.
24. Nettles R.E., Kieffer T.L., Kwon P., Monie D., Han Y., Parsons T., et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005, 293:817-829.
25. Palmer S., Maldarelli F., Wiegand A., Bernstein B., Hanna G.J., Brun S.C., et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2007, 105:3879-3884.
26. Deeks S.G. Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure. JAMA 2001, 286:224-226.
27. Ribaudo H., Lennox J., Currier J., Kuritzkes D., Gulick R., Haubrich R., et al. Virologic failure endpoint definition in clinical trials: is using HIV-1 RNA threshold <200copies/mL better than <50copies/mL? An analysis of ACTG studies. Abstract #580 presented at 16th Conference on Retroviruses and Opportunistic Infections, Montreal 2009 February, 16-19.
28. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2007. 19, Atlanta, GA, US Department of Health and Human Services, Centers for Disease Control and Prevention;2009:1-63. [accessed 15.3.11]. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/pdf/hivsur92.pdf.
29. Dinoso J.B., Kim S.Y., Wiegand A.M., Palmer S.E., Gange S.J., Cranmer L., et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 2009, 106:9403-9408.
30. McMahon D., Jones J., Wiegand A., Gange S.J., Kearny M., Palmer S., et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010, 50:912-919.
31. Taiwo B., Hicks C., Eron J. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1. J Antimicrob Chemother 2010, 65:1100-1107.